Physician profile
Mayur Patel
NPI 1629463427
$1,406.15
in general payments reported to CMS, 2019-2025
11 companies · $435 in 2025
The $435 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $255 · 2020: $124 · 2021: $184 · 2022: $58.37 · 2023: $61.41 · 2024: $288 · 2025: $435.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $689 · Grant: $95.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $689.33 |
| Grant | $95.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $347.43 | 2022-2025 | General - Therapies, General - Structural Heart, Lux-Dx Insertable Cardiac Monitor |
| Amgen INC. | $266.84 | 2020-2021 | |
| Medtronic Vascular, INC. | $255.39 | 2019 | |
| Heartflow, INC. | $206.30 | 2024-2025 | |
| Edwards Lifesciences Corporation | $103.22 | 2024 | Sapien 3 Ultra Resilia |
| Novo Nordisk INC | $96.26 | 2022-2024 | Wegovy, Ozempic, Rybelsus |
| Ge Healthcare | $36.45 | 2023 | |
| Jazz Pharmaceuticals INC. | $28.25 | 2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $24.79 | 2024 | Lifevest |
| Abbott Laboratories | $20.89 | 2021 | |
| Getinge USA Sales, LLC | $20.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mayur Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.